MedCity News May 2, 2024
Mariana Oncology brings Novartis a lead radiopharmaceutical program in development for small cell lung cancer. The deal is the latest in a string of big pharma M&A moves in the red-hot radiopharmaceuticals space.
Novartis is adding on to its capabilities in radiopharmaceuticals through a deal to acquire Mariana Oncology, a startup with a drug pipeline and technologies that diversify the pharmaceutical giant’s scope in this fast-growing area of cancer drug research.
According to the deal terms announced Thursday, Novartis is paying $1 billion up front. Milestone payments could bring the Mariana shareholders another $750 million.
Novartis is already a leader in radiopharmaceuticals with two commercialized therapies, Lutathera for gastroenteropancreatic neuroendocrine tumors and Pluvicto for prostate cancer. Both products employ the...
Today's Sponsors
Today's Sponsor